post-thumb

The FDA rejects a lung cancer drug from China

  • 2 Min To Read
  • in a day

F.D.A. Rejects Application for China-Developed Lung Cancer Drug

The Food and Drug Administration has rejected ivonescimab, a cancer treatment developed in China, according to Summit Therapeutics, the Florida company seeking approval to market it in the United States. Summit disclosed the decision on November 15, saying regulators found insufficient evidence that the treatment significantly prolonged patients’ lives.

The drug was invented by Akeso Biopharma, which sells it in China. Summit acquired the American rights and sought approval for certain patients with advanced lung cancer. The treatment has drawn attention as an example of China’s expanding role in pharmaceutical development, with additional studies examining its use against other cancers.

Summit’s application relied on a clinical trial conducted across the United States, Canada, Europe and Asia. Participants had previously received a targeted treatment. Researchers compared patients given ivonescimab alongside chemotherapy with patients receiving chemotherapy alone. The combination delayed cancer progression, but the study did not demonstrate a statistically significant improvement in overall survival.

According to Summit, that survival finding was the reason the F.D.A. declined to approve the application. The reported results distinguish between slowing the disease and establishing that patients live longer, two different measures of a treatment’s effects. In this case, the progression results did not resolve regulators’ concerns about survival.

Summit has attributed the lack of a demonstrated survival benefit to slow enrollment in the trial. To support its application, the company submitted additional analyses of patient outcomes over a longer period. Those analyses were not specified in the original research plan and did not persuade the agency to grant approval.

The decision concerns the specific lung cancer application, while ivonescimab is also being studied in cancers affecting the colon, bladder and breast. Those investigations extend beyond the patient group covered by Summit’s submission. The rejection leaves the company without the American marketing approval it had sought.

Share: